Core Viewpoint - The company Erkang Pharmaceutical (300267) showcases its strengths and development potential in the pharmaceutical excipients industry during the 2025 Hunan Listed Companies Collective Reception Day and Semi-Annual Performance Briefing held on September 19. Group 1: Company Strengths - The company offers a diverse range of products, with 127 pharmaceutical excipient varieties, accounting for 32.87% of the 387 varieties listed in the 2025 edition of the Chinese Pharmacopoeia, covering nearly all commonly used pharmaceutical excipients [1] - Established supply relationships with over 3,000 domestic downstream customers, indicating high product and customer stickiness [1] - Possesses three significant research platforms: the "National Pharmaceutical Excipients Engineering Technology Research Center," the "National Recognized Enterprise Technology Center," and the "Key Laboratory of Pharmaceutical Excipients Engineering Technology of the National Medical Products Administration" [1] - Actively participates in the formulation and revision of standards for pharmaceutical excipients in the Chinese Pharmacopoeia and contributes to the compilation of the "Infrared Spectrum Collection of Pharmaceutical Excipients" [1] - Awarded the qualification of "Variety Guardian" for 12 types of pharmaceutical excipients by the National Pharmacopoeia Committee [1] - Achievements in quality improvement research for injectable pharmaceutical excipients, with the project "Key Technology Development and Industrialization of Injectable Pharmaceutical Excipients" winning the second prize in Hunan Province's Science and Technology Progress Award [1] - The company's starch capsules and other varieties have been included in the list of key varieties in the biopharmaceutical industry chain published by the Hunan Provincial Department of Industry and Information Technology (second batch) [1]

Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd., is a significant event for the company, which may lead to changes in leadership but is not expected to disrupt its operations [1][3]. Group 1: Company Leadership - Yin Zhenglong passed away on August 26, 2025, at the age of 60, and had been the chairman and general manager since the company's inception [3][5]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. - The company announced that the board's functionality will remain intact, and the management team will continue its operations without interruption [3]. Group 2: Company Operations - Following Yin Zhenglong's death, the company will conduct a board election to fill the chairman position, with current director and general manager Song Daocai temporarily assuming the role [3][5]. - The company reported a revenue of 471 million yuan for the first half of 2025, a year-on-year increase of 4.65%, while the net profit attributable to shareholders was approximately 93 million yuan, a decrease of 2.61% [8]. - Basic earnings per share were reported at 0.40 yuan, down 2.44% year-on-year [8]. Group 3: Company Background - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, holding a leading position in the domestic market [8]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [8]. Group 4: Recent Developments - The company's official website has been changed to a black-and-white page, indicating a period of mourning [6]. - Yin Zhenglong had recently chaired a shareholders' meeting on August 18 and a board meeting on the morning of August 26, just hours before his passing [5].

Core Viewpoint - The chairman and actual controller of Shanhe Pharmaceutical Excipients, Yin Zhenglong, passed away at the age of 60, leading to a significant impact on the company's stock price and governance structure [1][3]. Company Overview - Shanhe Pharmaceutical Excipients is engaged in the research, production, and sales of pharmaceutical excipients, with main products including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms and injectable pharmaceutical excipients [2]. Impact of Chairman's Death - Following the announcement of the chairman's death, the company's stock price fell over 4%, closing at 13.64 yuan per share [3]. - The company’s official website has been changed to black and white as a sign of mourning [3]. - Yin Zhenglong was the founder and had served as chairman and general manager since the company's inception, playing a crucial role in its growth and listing on the Shenzhen Stock Exchange [3]. - He held 63,057,454 shares, representing 26.90% of the total shares, making him the controlling shareholder [3]. Governance Transition - The company announced that it will promptly complete the election of a new chairman according to relevant laws and regulations [3]. - In the interim, the current director and general manager, Song Daocai, will assume the responsibilities of chairman and legal representative until a new chairman is elected [3].

Core Points - The chairman and actual controller of the company, Yin Zhenglong, passed away on August 26, 2025, at the age of 60 [1][3] - Yin Zhenglong was the founder of the company and held 63,057,454 shares, accounting for 26.90% of the total shares, making him the controlling shareholder [3] - Following his passing, the board of directors appointed Song Daocai, a director and general manager, to temporarily assume the roles of chairman and legal representative until a new chairman is elected [3] - The company specializes in the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [3] - The company's official website turned black and white on August 27, 2025, in tribute to the deceased chairman [3]

Core Viewpoint - The sudden passing of Mr. Yin Zhenglong, the controlling shareholder, actual controller, and chairman of the company, has raised concerns about the future leadership and management of the company [1][3]. Company Overview - Anhui Shanhe Pharmaceutical Excipients Co., Ltd. was established in April 2001 and specializes in the production, research and development, and sales of new pharmaceutical excipients [6]. - The company is a leading player in the domestic pharmaceutical excipients (solid preparations) industry and was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 under the stock code 300452 [6]. - The company has a registered capital of 180.46707 million RMB and operates subsidiaries including Qufu Tianli Pharmaceutical Excipients Co., Ltd. (controlling) and Hefei Shanhe Pharmaceutical Technology Co., Ltd. (wholly-owned) [6]. Leadership Transition - Mr. Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder and actual controller [3]. - Following Mr. Yin's passing, the company announced that the board of directors would not fall below the legal number of members, ensuring normal operations [3]. - The company’s management team will continue to perform their duties, and the board will expedite the election of a new chairman [3]. - Mr. Song Daocai, a board member and general manager, has been temporarily appointed to fulfill the duties of chairman and legal representative until a new chairman is elected [3].

Core Points - The chairman and actual controller of the company, Yin Zhenglong, passed away on August 26, 2025, at the age of 60 [1][3] - Yin Zhenglong was the founder of the company and had held key positions since its establishment, including chairman and general manager [3] - He owned 63.0575 million shares, accounting for 26.9% of the total shares, making him the controlling shareholder [3] - The company will handle the transfer of shares according to relevant laws and regulations and will disclose information as necessary [3] - The board of directors has appointed Song Daocai, a director and general manager, to temporarily assume the roles of chairman and legal representative until a new chairman is elected [3] - The company specializes in the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [3] - As of August 26, 2025, the company's stock price was 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [3] - The number of shareholders as of June 30, 2025, was 17,500 [3]

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Excipients, marks a significant transition for the company, which has grown from a small local pharmaceutical factory to a leading player in the pharmaceutical excipients industry in China [1][2]. Company Overview - Shanhe Pharmaceutical Excipients was established in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, becoming a private joint-stock enterprise [2]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in May 2015 [2]. Leadership Transition - Following the death of Yin Zhenglong on August 26, 2025, the company announced that Song Daocai, the current director and general manager, will temporarily assume the roles of chairman and legal representative until a new chairman is elected [3]. Financial Performance - For the first half of 2025, the company achieved a total operating revenue of 471 million yuan, representing a year-on-year increase of 4.65% [3]. - The net profit attributable to shareholders was approximately 93.04 million yuan, a decrease of 2.61% compared to the previous year [3]. - The net profit after deducting non-recurring gains and losses was about 84.75 million yuan, reflecting a year-on-year growth of 6.05% [3]. Industry Position - Shanhe Pharmaceutical Excipients has positioned itself as a leader in the pharmaceutical excipients sector, with over 170 projects supporting the localization of excipients [2]. - The company offers a wide range of products, including 46 CDE registered products and holds 22 national invention patents, with several core products achieving the highest market share domestically [2].

Core Points - The sudden announcement of the death of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Excipients, occurred on August 26, 2025, at the age of 60 [1][5][7] - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder [7] - The company stated that Yin Zhenglong's death would not affect the normal operation of the board of directors, and the management team would continue to perform their duties [9] Company Background - Shanhe Pharmaceutical Excipients was founded in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, currently holding a leading position in the domestic market [11] - The company was successfully listed on the Shenzhen Stock Exchange in May 2015, with a current market value of approximately 3.28 billion yuan [11] - Under Yin Zhenglong's leadership, the company grew from a small local pharmaceutical factory to a publicly listed company [10] Financial Performance - For the first half of 2025, Shanhe Pharmaceutical Excipients reported a revenue of 471 million yuan, a year-on-year increase of 4.65%, while the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [12][13] - The company reported a significant increase in cash flow from operating activities, which rose by 108.53% compared to the previous year [13] - The basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [13]

Core Viewpoint - The announcement of the passing of Yin Zhenglong, the controlling shareholder and chairman of Anhui Shanhe Pharmaceutical Excipients Co., Ltd., marks a significant event for the company, as he was instrumental in its development and growth [5][6]. Group 1: Company Overview - Anhui Shanhe Pharmaceutical Excipients Co., Ltd. specializes in the research, production, and sales of pharmaceutical excipients, including fillers, binders, disintegrants, lubricants, and coating materials [3]. - As of August 26, 2025, the company's stock price was reported at 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [4]. Group 2: Leadership Transition - Following the death of Yin Zhenglong, the company will not experience a reduction in the number of board members below the legal requirement, and the management team will continue to operate normally [7]. - Song Daocai, the current general manager, has been appointed to temporarily assume the responsibilities of chairman and legal representative until a new chairman is elected [7].

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant event for the company, which he led for over 20 years, establishing it as a key player in the pharmaceutical excipients industry [4][5][6]. Company Overview - Shanhe Pharmaceutical Auxiliary announced the death of its controlling shareholder and chairman, Yin Zhenglong, on August 26, 2025, at the age of 60 [1]. - The company has updated its official website to a black-and-white page as a sign of mourning [2]. - Yin Zhenglong chaired the sixth board meeting on the morning of August 26, where two key proposals were approved, including the half-year report for 2025 [4]. Leadership and Vision - As the founder, Yin Zhenglong played a crucial role in the company's growth from a local pharmaceutical factory to a publicly listed entity on the Shenzhen Stock Exchange [5]. - He emphasized the importance of "technical marketing" and "pre-marketing," advocating for sales personnel to possess technical knowledge to provide solutions to clients [4]. - Yin aimed to replace imported pharmaceutical excipients with domestic products, which was a key development goal for the company [4]. Shareholding and Management Transition - Yin Zhenglong held 26.90% of the company's shares, making him the controlling shareholder [6]. - The company stated that the inheritance of his shares will be handled according to legal regulations, and the board's operations remain unaffected [6]. - Song Daocai, a board member and general manager, has been appointed as the interim chairman and legal representative until a new chairman is elected [6].